
NovartisNVS
Pharmaceuticals
$160.79−0.19%After hours: $161.10 (+0.19%)At the close, 30 Oct · Prices from CNBC, may be delayed
Source: Nasdaq daily closes
Source: Nasdaq daily closes
Source: Nasdaq daily closes
Source: Nasdaq daily closes
Source: Nasdaq daily closes
Market value$327B
Price to earnings30.8x
Forward P/E17.0x
Dividend yield2.95%
Year to date+16.6%
One year+32.0%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$122.61$168.62
Quality and valuation
How Novartis compares with other health care stocks. A description, not a recommendation.
Stronger business ↑↓ Weaker business← Pricier · 36x10x · Cheaper →Stronger, pricierStronger, cheaperWeaker, pricierWeaker, cheaper
LLY
JNJ
MRK
PFE
BMY
LLY
JNJ
MRK
PFE
BMYNovartis and 4 pharmaceuticals peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.
Valuation: in line with its sector
Next to other health care companies, it is, priced about in line with them.
Novartis trades at 17.0 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover.
Source: CNBC quotes; Mostly Markets
Stories on Novartis
We haven't written about Novartis yet. Follow it, and its first story will show under My stocks on the front page.
Similar companies
Pharmaceuticals, by market value.
| Company | Price | Today |
|---|---|---|
LLYEli Lilly | $1,417.54 | +3.19% |
JNJJohnson & Johnson | $273.20 | −0.73% |
MRKMerck | $149.52 | +2.18% |
AZNAstraZeneca | $186.65 | +7.02% |
PFEPfizer | $30.52 | +1.90% |
NVONovo Nordisk | $40.00 | +2.20% |
BMYBristol Myers Squibb | $62.48 | +1.78% |
ZTSZoetis | $79.72 | +1.85% |


